2021 American Transplant Congress
Cost-Effectiveness Analysis of Short-Duration Anti-Viral Prophylaxis for Hepatitis C Positive Donor Kidney Transplants
Virginia Commonwealth University Health System, Richmond, VA
*Purpose: Trials describing 4-12 week courses of direct-acting anti-viral drugs (DAAs) to treat hepatitis C virus (HCV) transmission from infected donors to uninfected kidney transplant…2021 American Transplant Congress
Are Tacrolimus Concentrations Reduced with Direct-acting Antiviral Administration in Transplant Recipients?
Pharmacy, Penn State Health Hershey Medical Center, Hershey, PA
*Purpose: To evaluate the effects of direct-acting antivirals (DAAs) on tacrolimus trough concentrations and clinical outcome and to assess the need for a priori dose…2021 American Transplant Congress
Outcomes of Kidney Transplantation from Hepatitis C Virus (HCV) Infected Donors Stratified by Recipient HCV Serostatus: A Mate Kidney Analysis
*Purpose: Kidneys from donors infected with hepatitis C virus (HCV) are increasingly used for transplantation into HCV positive (+) recipients historically and into HCV negative…2021 American Transplant Congress
Outcomes of Hepatitis C Nucleic Acid Testing Positive Donors in Aviremic Recipients With Delayed Direct-Acting Antiviral Initiation
Pharmacy, Tampa General Hospital, Tampa, FL
*Purpose: The purpose of this study was to assess the clinical impact of utilizing hepatitis C virus (HCV) nucleic acid testing (NAT)+ donors in HCV…2021 American Transplant Congress
Transplanting Hepatitis C Infected Organs Into Uninfected Recipients: A Pharmacy Perspective
University of Alabama at Birmingham Hospital, Birmingham, AL
*Purpose: Due to direct acting antivirals (DAAs), hepatitis C virus (HCV) positive patients are now resources for organ transplantation in HCV negative recipients. Our institution…2021 American Transplant Congress
Use of Donor Blood Expedites HCV Genotyping and Allows Earlier DAA Initiation for Recipients of HCV+ Kidneys
Tranplant Institute, NYU Langone Health, New York, NY
*Purpose: Utilization of HCV viremic donor kidneys for transplant into HCV naïve recipients has become more widespread, yet best practices governing the initiation, timing or…2021 American Transplant Congress
Pilot Study for the Use of Shortened Preemptive Therapy with Glecaprevir/pibrentasvir (g/p) and Ezetimibe in Hepatitis C Seronegative Solid Organ Transplant Recipients (Kidney and Heart) of Hepatitis C Viremic Donors
*Purpose: This prospective study aims to assess the efficacy of preemptive therapy with eight days of a combination of direct-acting antivirals (DAAs) (Mavyret) (Pibrentasvir /Glecaprevir)…2021 American Transplant Congress
The Use of Hcv Nat+ Organs in Hcv Negative Recipients with On-site Specialty Pharmacy Services: A Win for the Patient, the Transplant Center, and Society?
Medical University of South Carolina, Charleston, SC
*Purpose: Use of HCV AB positive organs (HCV AB+) with active viremia (NAT+) relies on appropriate and timely use of direct acting antiviral therapies (DAA).…2021 American Transplant Congress
Evaluation and Experience with Hepatitis C Positive to Negative PancreasTransplantation
Medstar Georgetown University Hospital, Washington, DC
*Purpose: The use of hepatitis C virus (HCV) positive organs for transplant to HCV negative recipients has been reported on and has gained popularity across…2021 American Transplant Congress
Successful Single-Center Experience Using HCV+ Organs for Single and Dual-Organ Transplantation
*Purpose: National data demonstrate that increasing organ transplantation opportunities exist from hepatitis C virus (HCV)-infected individuals to HCV negative recipients.*Methods: We developed a clinical practice…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 28
- Next Page »